193 A doseresponse analysis of CoQ10 in migraine suggested a non-linear association with maximal efficacy at 300 mg daily regardless of variation in bioavailability of different formulations
A team of researchers developed a nanostructure-based GLP-1R agonist capable of crossing the BBB that significantly attenuated neuroinflammation and memory loss in an A peptide-induced mouse model of AD by inhibiting the inflammatory responses of microglia and astrocytes (Zhao et al., 2022)
Mary Watanabe Person We've added the 10 business behavioral health follow up appointment standard into our methodology for monitoring timely access, which was implemented in measurement year 2023 and set an 80% performance target
Naltrexone/bupropion (Mysimba) is contraindicated in end-stage renal disease and requires dose reduction in moderate renal impairment, as specified in its Summary of Product Characteristics
10.1016/s0140-6736(09)60318-4 2
A., Hammoud, R., Rittig, N., & Drucker, D